
The consumer health group lowered its 2026 revenue growth outlook as cough, cold and flu sales weighed on third-quarter performance.
Haleon cut its revenue growth target to 2.5% from a previous range of 3% to 5%, citing weak demand for cough, cold and flu medicines. The company said third-quarter organic revenue growth was 2.6%, below expectations.
The slowdown in flu medicine demand reduced North American sales growth to 2.5% from 3.1%. Higher demand for Sensodyne toothpaste provided a brighter spot, while European revenue fell 0.6%, partly due to weak Centrum sales.
Haleon shares fell more than 11% to 333 pence in early trading, according to City A.M. As of Thursday afternoon, they traded at 314.79 pence, down 15.83% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.